By webmin on
Phone
N/A
Email
expandedaccess@scynexis.com
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=&spons=scynexis&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d
Acknowledgement
24 hours
EA Page
http://www.scynexis.com/science/expanded-access.php
EA Therapies for Single Patient

SCY-078 is a triterpenoid, glucan synthase inhibitor, antifungal agent undergoing investigation for:
•    The treatment of invasive candidiasis, including candidemia (IC). 
•    The treatment of invasive aspergillosis (IA), including IA that is refractory to or intolerant of other antifungal therapies.
•    The treatment of invasive candidiasis in patients who are refractory to or intolerant of other antifungal therapies.

EA Policies for Single Patient

SCYNEXIS is committed to making Investigational Products available to seriously ill patients who have exhausted other treatment options.  A treating physician, who is able to comply with the SCYNEXIS requirements, may request information about how to apply for access to SCYNEXIS’ Investigational Products by contacting the company.